Translating genetic data in Alzheimer’s into potential therapies with Owen Peters

Written by Sharon Salt, Editor

Although risk genes for Alzheimer’s increase the likelihood of an individual developing the disease, it does not guarantee that it will happen. Not every person who has one or even two APOE4 genes develop Alzheimer’s disease, and it can even occur in people who don’t even have an APOE4 gene. Researchers also suspect that many more genes that haven’t been identified yet can affect the risk of developing the disease.

To find out more about risk genes and Alzheimer’s disease, we spoke with Owen Peters (UK DRI at Cardiff University, UK) at the UK–Korea Neuroscience Symposium (12–13 August, London, UK). In this interview, Owen speaks to us about the challenges associated with identifying risk genes for Alzheimer’s disease and how these challenges might be overcome. He also provides his opinions on what more needs to be done to successfully translate this genetic information into potential therapeutics.

Interview questions for Owen Peters on risk genes in Alzheimer’s disease:

00:05 – Please can you introduce yourself and tell us more about your role?

00:11 – Could you give us an overview of your research?

00:20 – What are the challenges associated with identifying risk genes for Alzheimer’s disease?

01:50 – How might these challenges be overcome?

02:21 – What more needs to be done to successfully translate this genetic information into potential therapeutics?

03:08 – Lastly, where do you hope to see the field in 5–10 years’ time?

You might also like:

Disclaimer
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Neuro Central or Future Science Group.